ReviewJournal of human hypertension2013
An update on the genetics of pheochromocytoma.
Review in Journal of human hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.European journal of nuclear medicine and molecular imaging · 2012Guideline
- CLINICAL EVALUATION, DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA.Acta clinica Croatica · 2024Review
- Phaeochromocytoma in a patient with a Birt-Hogg-Dubé syndrome phenotype.BMJ case reports · 2023Article
- Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach.International journal of molecular sciences · 2022Review
- Atypical variant takotsubo cardiomyopathy secondary to pheochromocytoma.Proceedings (Baylor University. Medical Center) · 2022Article
- Concurrent Urinary Bladder Paraganglioma and Adrenal Phaeochromocytoma With Succinate Dehydrogenase-B Mutation.Cureus · 2021Article
- Neurological Complications of Endocrine Emergencies.Current neurology and neuroscience reports · 2021Review
- Tako-tsubo Syndrome as First Manifestation in a Case of Pheochromocytoma Developed From a Non-functional Adrenal Incidentaloma.Frontiers in endocrinology · 2020Article
- A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.Neoplasma · 2019Review
- Unsuspected Von Hippel-Lindau syndrome in acute-onset resistant hypertension.BMJ case reports · 2018Article
- Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy.Experimental and therapeutic medicine · 2018Article
- A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?International journal of endocrinology · 2018Review
- The clinical genetics of phaeochromocytoma and paraganglioma.Archives of endocrinology and metabolism · 2017Review
- Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.Iranian journal of pathology · 2017Review
- (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Article
- Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.Endocrinology · 2015Article
- Article
- Familial pheochromocytomas and paragangliomas.Molecular and cellular endocrinology · 2014Review
- High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors. About 30% or more of them are thought to be of inherited origin due to germ-line mutations in at least 10 well-characterized genes. There are data linking specific genotypes of these tumors to specific locations, typical biochemical phenotypes or future clinical behaviors. Conversely, clinical features, catecholamine production and immunohistochemistry evaluation can help with the proper order of genetic testing for PHEO and PGL. The identification of a germ-line mutation can lead to an early diagnosis, appropriate treatment, regular surveillance and better prognosis not only for the patient but also for their family members. Moreover, the latest discoveries in molecular pathogenesis of these tumors will provide an important basis for future personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.